I recently caught up with someone who is moving into an investing role at a venture capital firm – she asked me for any book recommendations that could help her get up to speed faster
I’ve shared versions of this list a few times prior in emails and thought it may be interesting to share more broadly.
At core, I think the best investors are learning machines – they are curious about new things + people and have an internal hunger + drive which that has them focus on the process versus outcome
Through that lens, I think the best reading resources provide a base layer of knowledge on how technology impacts markets + the related business theory – to set a foundation to understand new opportunities more quickly and deeply
First, three books on financing innovation + technology market cycles
Bill Janeway – Doing Capitalism in the Innovation Economy
Carlota Perez – Technological Revolutions and Financial Capital
Eric Beinhocker – The Origins of Wealth
The next set of books focus on understanding business strategy + corporate finance for high growth companies
William Thorndike – The Outsiders
Michael Porter – Competitive Strategy
Hamilton Helner – 7 Powers
On top of the theory – the last set of books is all around history – of the industry + specific companies
Elad Gil – High Growth Handbook
Tom Nichols – VC
Jessica Livingston – Founders at Work
As a bonus, I recommend reading S-1 filings of recent IPOs – these documents often offer amazing insights into what great businesses look like at scale
And Bill Gurley’s blog
It is filled with great analysis – like this post on elements of the 10x revenue club:
Lastly, there are a bunch of good books on the day-to-day mechanics of the business of venture capital – I think you’ll able to pick up on the job, so I would prioritize the list above – but more if you’re curious:
Brad Feld, Jason Mendelson – Venture Deals
Jeff Bussgang – Mastering the VC Game
If you ever have any questions about these types of topics – I’d highly recommend Mark Suster’s blog
I recently had a conversation with Chas Pulido and Dennis Gong of Alix Ventures for the BIOS Podcast where we discussed how scientists thinking about starting companies can appeal to investors, including how we think about it at True.
I also shared how True started investing in startups tackling problems in human health and biology, as well as our founder-focused investment model that’s guided us since day one.
The conversation was fun and hopefully provides some context for scientist-founders and investors looking to spend more time in this space.
Over the past two decades, we’ve seen hundreds of billions of dollars of market capitalization created by new software and infrastructure companies built at the intersection of mobile, data, and cloud computing.
Now, we’re in the middle of an even larger shift at the intersection of biology, software, and automation as old industries are reimagined and entirely new ones are created. These new products that are inspired by nature and built with biology are better for consumers, better for the environment, and higher performing than what their predecessors developed with harsh chemicals and petroleum.
Looking forward, we’re excited to see what comes next as the technologies these companies are building lead to the creation of new and better products in even more markets, including food, B2B materials, consumer goods, healthcare, and agriculture.
As our population grows in size and income, we will increasingly need access to larger amounts of high quality, healthy food, especially protein. One way this will happen is through the creation of new, great-tasting plant-based alternatives to meat.
Prime Roots started with a plant-based salmon burger, which Fast Company said “tastes like the real thing” and The Wall Street Journal’s food writer Alison Roman described as having the “flaky texture of America’s favorite fish.” Since then, the company has used its technology to develop products that resemble other protein types too, including chicken, beef, and pork.
The company grew out of a passionate community the founders developed online. This allowed them to better understand what types of products the consumer really wants and develop proprietary recipes that taste great, in addition to being healthy and better for the environment. While their earliest adopters were mostly individuals who were already vegan or vegetarian, most of their newest customers are individuals who just want to eat less meat.
Another way we’ll be able to increase access to nutritious, sustainably produced food is by using cellular agriculture to complement conventional livestock farming. Companies in this space, such as pork producer Fork & Goode, are reinventing the full supply chain to not only make real meat that people want, but also food that is safer to eat, is nutritionally equivalent to farm-raised livestock, and has a far lower environmental footprint.
The last century was dominated by the use of harsh chemical processes that manipulate petroleum in order to create new products. The next 100 years will be about innovating with biology to bring never-before-imagined products and materials to market. Nature has always provided a much broader resource set than chemicals, but we were unable to develop great, high-performing products without recent developments in software and automation, which let us better harness its insights.
Zymergen combines biology, machine learning, and automation to bio-manufacture products for Fortune 1,000 partners in electronics, agriculture, personal care, and other industries. For example, the team developed adhesives using biological derivatives that are similar to those made naturally by mussels, with significantly better bonding strength than other adhesives on the market today.
Another early entrant in this space is Modern Meadow, which developed a replacement for leather and sells it to partners in fashion, automotive, and more. In addition to the positive environmental impact of companies like these, they let brands better react to shifts in consumer preferences and build products previously not thought possible.
To take advantage of this innovation in materials science, more and more emerging brands are developing new, innovative products they sell directly to consumers. These products could have never been built prior, without business models designed from the ground up for modern consumers.
Hair color and care brand Madison Reed did the hard work of creating incredibly high-quality Italian-grade hair color, but without the harsh chemicals found in similar products. Moreover, Madison Reed compounded that by creating a business model that supports their customers with a lively community of peer reviews and body-positive messaging.
Another example is Symbiome, which is developing products inspired by this team’s unique understanding of ancestral human health. The core data asset that drives Symbiome’s approach to skincare is a proprietary map of ancestral bacterial diversity and ancestral plant foliage that used to exist but was lost due to stress and environmental factors over time.
In addition to building effective products, the company is committed to building clean products with as few ingredients as possible. In Symbiome’s initial collection, no product has more than five ingredients. Long term, the company is striving to keep the number of ingredients in any single product to eight or less, with zero use of harsh chemicals.
We’re also seeing early examples of how these trends can spur the creation of new product categories with a material impact on the global healthcare system.
Membio is developing a method to produce red blood cells outside of the human body for health and therapeutic applications. In the short-term, this company can provide a novel delivery mechanism for specific types of gene therapy products. Long-term, Membio can provide an alternative source of red blood cells for patients that would reduce the risk of potential issues with donor blood and other supply chain issues.
We’re in the earliest days of this convergence of biology, software, and automation and think the intersection of these technology trends will be compounded by a shift in consumer demographics and new business models.
As we’ve shared these ideas with others, we’ve heard this space called “deep technology” or “frontier technology.” We’d instead argue that this convergence is merely a reflection of what venture capital was intended to do: combine the best of multiple disciplines to create new markets and reshape existing markets, while ultimately leading to high-margin businesses with predictable revenue, highly differentiated product, and real defensibility.
As discussed in a previous post, we think bridging the two worlds between what we consider to be “life science VCs” and “technology VCs” — and bringing together validated technology and validated business models in new ways — is where the most interesting new companies will emerge.
It isn’t new discovery or research; it is engineering and business model iteration. Individuals who are willing to learn more about this convergence are best positioned as these next-wave companies come to life.